Book contents
- Stories of Stroke
- Stories of Stroke
- Copyright page
- Contents
- Contributors
- Why This Book Needed to Be Written
- Preface
- Part I Early Recognition
- Part II Basic Knowledge, Sixteenth to Early Twentieth Centuries
- Part III Modern Era, Mid-Twentieth Century to the Present
- Types of Stroke
- Some Key Physicians
- Imaging
- Care
- Treatment
- Chapter Forty Three Clinical Stroke Trials
- Chapter Forty Four Heparin
- Chapter Forty Five Warfarin
- Chapter Forty Six Direct Oral Anticoagulants
- Chapter Forty Seven Aspirin
- Chapter Forty Eight Other Antiplatelets
- Chapter Forty Nine Other Medical Treatments
- Chapter Fifty Neuroprotection
- Chapter Fifty One Thrombolysis
- Chapter Fifty Two Treatment of Cerebral Venous Thrombosis
- Chapter Fifty three Recovery and Rehabilitation
- Chapter Fifty Four Carotid Artery Surgery
- Chapter Fifty Five Angioplasty and Stenting
- Chapter Fifty Six Endovascular Treatment of Acute Ischemic Stroke
- Chapter Fifty Seven Brain Aneurysm Treatment
- Chapter Fifty Eight Medical and Surgical Treatments of Intracerebral Hemorrhage
- Chapter Fifty Nine Treatment of Vascular Malformations
- Part IV Stroke Literature, Organizations, and Patients
- Index
- References
Chapter Forty Nine - Other Medical Treatments
from Treatment
Published online by Cambridge University Press: 13 December 2022
Book contents
- Stories of Stroke
- Stories of Stroke
- Copyright page
- Contents
- Contributors
- Why This Book Needed to Be Written
- Preface
- Part I Early Recognition
- Part II Basic Knowledge, Sixteenth to Early Twentieth Centuries
- Part III Modern Era, Mid-Twentieth Century to the Present
- Types of Stroke
- Some Key Physicians
- Imaging
- Care
- Treatment
- Chapter Forty Three Clinical Stroke Trials
- Chapter Forty Four Heparin
- Chapter Forty Five Warfarin
- Chapter Forty Six Direct Oral Anticoagulants
- Chapter Forty Seven Aspirin
- Chapter Forty Eight Other Antiplatelets
- Chapter Forty Nine Other Medical Treatments
- Chapter Fifty Neuroprotection
- Chapter Fifty One Thrombolysis
- Chapter Fifty Two Treatment of Cerebral Venous Thrombosis
- Chapter Fifty three Recovery and Rehabilitation
- Chapter Fifty Four Carotid Artery Surgery
- Chapter Fifty Five Angioplasty and Stenting
- Chapter Fifty Six Endovascular Treatment of Acute Ischemic Stroke
- Chapter Fifty Seven Brain Aneurysm Treatment
- Chapter Fifty Eight Medical and Surgical Treatments of Intracerebral Hemorrhage
- Chapter Fifty Nine Treatment of Vascular Malformations
- Part IV Stroke Literature, Organizations, and Patients
- Index
- References
Summary
Advances in stroke prevention and improvement in the care and management of stroke patients can, in a large measure, be attributed to advances in knowledge about various medical conditions and their treatment. These stories of stroke could not be written without some attention to the medical risk factors and comorbidities prevalent in stroke patients. Many books would be needed to cover all the medical history. Some information is covered in Chapter 38 on epidemiology and stroke prevention. This chapter includes brief clips about the development of knowledge and ideas concerning major important medical conditions and their management.
- Type
- Chapter
- Information
- Stories of StrokeKey Individuals and the Evolution of Ideas, pp. 465 - 477Publisher: Cambridge University PressPrint publication year: 2022
References
Notes and References
Caplan, LR. Vertebrobasilar Ischemia and Hemorrhage: Clinical Findings, Diagnosis, and Management of Posterior Circulation Disease. Cambridge: Cambridge University Press, 2014, pp. 215–216.Google Scholar
Bruenn, HG. Clinical notes on the illness and death of president Franklin D. Roosevelt. Ann. Intern. Med. 1970;72:579–591.Google Scholar
Smithwick, R. H. Hypertensive cardiovascular disease: Effect of thoracolumbar splanchnicectomy on mortality and survival rates. JAMA 1951;147:1611–1615.Google Scholar
Saklayen, MG, Deshpande, N. Timeline of history of hypertension treatment. Front. Cardiovasc. Med. 2016;3:3. doi: 10.3389/fcvm.2016.00003.Google ScholarGoogle Scholar
Guyton, AC. Blood pressure control: Special role of kidneys and body fluid. Science 1991;252:1813–1816.CrossRefGoogle Scholar
Freis, ED, Wanko, A, Wilson, IM, Parrish, AE. Treatment of essential hypertension with chlorothiazide (diuril); its use alone and combined with other antihypertensive agents. JAMA 1958;166:137–140.Google Scholar
Black, James W.. Lindau Nobel Laureate Meetings. Available at www.mediatheque.lindau-nobel.org/laureates/black.Google Scholar
Castle, WB. George Richards Minot. Biographical Memoirs of the National Academy of Sciences 1974;45:337–383.Google Scholar
Rosenfeld, L. Insulin: Discovery and controversy. Clin. Chem. 2002;48:2270–2288.Google ScholarGoogle Scholar
White, JR Jr. A brief history of the development of diabetes medications. Diabetes Spectr. 2014;27(2):82–86.CrossRefGoogle ScholarPubMed
Reaven, G. Syndrome X, a short history. Ochsner J. 2001;3(3):124–125.Google ScholarGoogle ScholarGoogle Scholar
Kannel, WB, Dawber, TR, Friedman, GD, Glennon, WE, McNamara, PM. Risk factors in coronary heart disease: An evaluation of several serum lipids as predictors of coronary heart disease; the Framingham Study. Ann. Intern. Med. 1964;61:888–899.Google Scholar
Golding, SS, Allen, NB. Cholesterol and atherosclerotic cardiovascular disease: A lifelong problem. J. Am. Heart Assoc. 2019;8(11):e012924.Google Scholar
Duncan, MS, Vasan, RS, Xanthakis, V. Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all‐cause mortality: Observations from the Framingham Study over 35 years. J. Am. Heart Assoc. 2019;8:e011433.Google Scholar
Goldstein, Joseph L., biographical. The Nobel Prize. Available at www.nobelprize.org/prizes/medicine/1985/goldstein/biographical/.Google Scholar
Goldstein, JL, Brown, MS. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 2009;29(4):431–438.CrossRefGoogle ScholarPubMed
Brown, Michael S., biographical. The Nobel Prize. Available at www.nobelprize.org/prizes/medicine/1985/brown/biographical/.Google Scholar
Endo, A. A historical perspective on the discovery of statins. Proc. Japan Academy Ser. B Phys. Biol. Sci. 2010;86(5):484–493.Google ScholarGoogle ScholarGoogle Scholar
Amarenco, P, Goldstein, LB, Szarek, M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007;38:3198–3204.Google ScholarGoogle Scholar
Karatasakis, A, Danek, B, Karacsonyi, J, et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: A meta-analysis of 35 randomized controlled trials. J. Am. Heart Assoc. 2017;6(12):e006910. doi: 10.1161/JAHA.117.006910.Google ScholarGoogle Scholar
Banach, M, Duell, PB, Gotto, AM Jr, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol. 2020 Jul 1. doi: 10.1001/jamacardio.2020.2314 (Epub ahead of print).CrossRefGoogle Scholar